A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Helene Duhamel was recently diagnosed with non-small cell squamous cell lung cancer. Duhamel shares her thoughts on her ...

Ratio Therapeutics, which specializes in the growing field of radiopharmaceuticals, has inked a deal to build a new research ...

"Most patients treated for small cell lung cancer experience rapid progression of disease and there is a high unmet need in the advanced setting," he added. "These interim results from the first ...

Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to ...

Puma Biotechnology Inc (PBYI) reports increased revenue and strategic expansions, despite facing inventory and income declines.

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung cancer (SCLC).

At March 31, 2025, the Company's cash and cash equivalents grew to $938.5 million, compared to $912.8 million at December 31, 2024, after prepaying a $50.0 million deposit related to our Evergreen ...